- Home
- SNGX vs CERO Comparison
SNGX vs CERO Comparison
Compare SNGX & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CERO
- Stock Information
- Founded
- SNGX 1987
- CERO 2017
- Country
- SNGX United States
- CERO United States
- Employees
- SNGX N/A
- CERO N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- SNGX Health Care
- CERO
- Exchange
- SNGX Nasdaq
- CERO Nasdaq
- Market Cap
- SNGX 7.4M
- CERO 8.4M
- IPO Year
- SNGX 1987
- CERO N/A
- Fundamental
- Price
- SNGX $2.35
- CERO $2.34
- Analyst Decision
- SNGX
- CERO
- Analyst Count
- SNGX 0
- CERO 0
- Target Price
- SNGX N/A
- CERO N/A
- AVG Volume (30 Days)
- SNGX 619.7K
- CERO 80.5M
- Earning Date
- SNGX 03-14-2025
- CERO 02-20-2025
- Dividend Yield
- SNGX N/A
- CERO N/A
- EPS Growth
- SNGX N/A
- CERO N/A
- EPS
- SNGX N/A
- CERO N/A
- Revenue
- SNGX $364,183.00
- CERO N/A
- Revenue This Year
- SNGX N/A
- CERO N/A
- Revenue Next Year
- SNGX $76.64
- CERO N/A
- P/E Ratio
- SNGX N/A
- CERO N/A
- Revenue Growth
- SNGX N/A
- CERO N/A
- 52 Week Low
- SNGX $1.83
- CERO $2.22
- 52 Week High
- SNGX $14.88
- CERO $1,280.00
- Technical
- Relative Strength Index (RSI)
- SNGX 34.04
- CERO 32.54
- Support Level
- SNGX $2.03
- CERO $2.83
- Resistance Level
- SNGX $3.44
- CERO $3.50
- Average True Range (ATR)
- SNGX 0.33
- CERO 1.13
- MACD
- SNGX -0.08
- CERO 0.05
- Stochastic Oscillator
- SNGX 19.39
- CERO 1.43
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.